At the conclusion of our educational meeting, the participant will be able to:
- Recognize the clinical significance of molecular genotyping of lung cancer patients.
- Understand the molecular pathways that hold promise for therapeutic intervention in lung cancer patients.
- Discuss the optimal methodology of clinical trials in the era of translational research.
- Recognize the importance of a multidisciplinary approach to the care lung cancer patients.